A groundbreaking international clinical trial has begun, testing a new form of CAR-T cell therapy specifically designed for children and young adults with solid cancers, a group that has seen minimal survival improvements in decades. The UK arm of the trial, named MIGHTY, has enrolled its first participant, a young adult in their early 20s, marking a significant step in addressing a critical unmet need in oncology.
The trial is led by the global NexTGen team, which is tackling the unique challenges of treating solid tumors in younger patients. Unlike blood cancers, where CAR-T therapy has been revolutionary, solid tumors form dense masses that create physical barriers and a hostile microenvironment to evade immune attack. The NexTGen approach engineers a patient's own T-cells to withstand this environment and target a protein called B7-H3, which is found on most solid tumors in children and young people. This precision aims to direct the immune cells to bind to and destroy the cancer.
This focus is vital because cancers in the young are biologically distinct from adult cancers. Treatments have historically been repurposed from adult regimens, often with harsh side effects for developing bodies. "We urgently need to shift away from simply repurposing adult cancer drugs and focus on developing treatments specifically for younger patients," said Dr. Karin Straathof, Lead Investigator for the MIGHTY trial. The trial notably includes patients up to their early 20s, breaking past traditional age cut-offs that have limited research and access for teenagers and young adults.
The NexTGen team will test their novel CAR-T cell therapy in up to 60 children and young people across sites in the UK and the US. For advocates like Sara Wakeling, who lost her daughter to rhabdomyosarcoma, the work carries profound hope. "Families shouldn't have to powerlessly watch their children die because no effective treatment options exist," she said. The trial represents a concerted global effort to deliver gentler, more effective solutions shaped by the unique biology of young people's cancers, offering a new path forward where one has been desperately needed.